Literature DB >> 8626380

Contrasting in vivo effects of murine and human apolipoprotein A-II. Role of monomer versus dimer.

E L Gong1, L J Stoltfus, C M Brion, D Murugesh, E M Rubin.   

Abstract

The role of apolipoprotein A-II (apoA-II) in high density lipoprotein (HDL) structure and metabolism has been studied previously in transgenic mice overexpressing either human or murine apoA-II. These studies have shown differences between these two groups of transgenic animals in the levels of very low density, low density, and high density lipoproteins, in the HDL particle size distribution, and in the relationship between apoA-II levels and lipoprotein levels. To determine whether these differences are due to the fact that human apoA-II is dimeric and murine apoA-II monomeric, we have examined the effects of monomeric human apoA-II (hA-IImon) in transgenic mice. Site-directed mutagenesis (Cys6 -> Ser) was used to generate 15 transgenic founder lines of hA-IImon mice, that contained plasma hA-IImon concentrations over a 10-fold range (11 mg/dl to 185 mg/dl). The hA-IImon floated in the d < or = 1.21 g/ml fraction and migrated as an apoA-II monomer by nonreducing SDS-polyacrylamide gel electrophoresis. HDL levels were not correlated with hA-IImon levels (r = -0.26); HDL particle size and size distribution, as well as very low density and low density lipoprotein levels and sizes, were unchanged compared to nontransgenic control mice. These results suggest that differences between mice overexpressing human dimeric apoA-II and those overexpressing murine apoA-II are the result of sequence differences between these two apoA-II molecules and are not solely due to the fact that human apoA-II exists as a dimer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626380     DOI: 10.1074/jbc.271.11.5984

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

2.  Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.

Authors:  P Holvoet; S Danloy; E Deridder; M Lox; H Bernar; A Dhoest; D Collen
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

3.  Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes.

Authors:  Ida Azizkhanian; Olgica Trenchevska; Yara Bashawri; Jiaqi Hu; Juraj Koska; Peter D Reaven; Randall W Nelson; Dobrin Nedelkov; Hussein N Yassine
Journal:  J Clin Lipidol       Date:  2016-03-08       Impact factor: 4.766

Review 4.  Wnt modulators in the biotech pipeline.

Authors:  Jean-Philippe Rey; Debra L Ellies
Journal:  Dev Dyn       Date:  2010-01       Impact factor: 3.780

5.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

Review 6.  HDL: bridging past and present with a look at the future.

Authors:  Angelo M Scanu; Celina Edelstein
Journal:  FASEB J       Date:  2008-08-20       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.